We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multiple Myeloma Sequences Reveal Prognostic Immunoglobulin Translocation

By LabMedica International staff writers
Posted on 08 May 2019
Multiple myeloma is the second most common hematological cancer, which affects terminally differentiated antibody secreting B cells, known as plasma cells. More...
Clinical manifestations of myeloma include hypercalcemia, anemia, renal failure, and lytic bone lesions.

Genetic analyses of myeloma over the last quarter century have revealed a bifurcation of founding genetic alterations with approximately half of myelomas containing an immunoglobulin heavy chain (IgH) translocation. The other myelomas are hyperdiploid, which is an aneuploidy of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21.

Hematologists at the Emory University School of Medicine (Atlanta, GA, USA) and their colleagues used whole-genome sequence data for samples from nearly 800 multiple myeloma patients profiled for the longitudinal Multiple Myeloma Research Foundation-funded "Clinical Outcomes in Multiple Myeloma to Personal Assessment," or CoMMpass study, including cases from North America and Europe, and searched for structural variants with potential ties to survival. Recurrent translocations involving the immunoglobulin lambda (IgL) antibody locus may provide previously unappreciated clues to treatment response and patient outcomes in multiple myeloma.

RNA-seq libraries were constructed with the TruSeq RNA Library Prep Kit v2, which yields unstranded mRNA libraries. The team used 150–2000 ng of RNA, which had an RNA integrity number of eight or higher for starting material. RNA libraries were amplified for 8–10 cycles and then sequenced on an Illumina HiSeq2000 or HiSeq2500 using v3 or v4 chemistry and 82 bp paired-end reads. Many other procedures and methods were also used.

A comprehensive analysis of structural variants in multiple myeloma was conducted using long-insert whole-genome paired-end sequencing performed on DNA isolated from CD138+ myeloma cells and normal peripheral blood to determine cancer-specific somatic alterations. The results of the study suggested that rearrangements that linked IgL to oncogenes such as MYC are associated with resistance to a standard multiple myeloma treatment called lenalidomide. Multiple myeloma patients with the risky IgL translocations also had shorter-than-usual survival times, the investigators reported, and were about half as likely to survive for at least three years compared to IgL-translocation-free cases.

With the help of chromatin immunoprecipitation sequencing on three myeloma cell lines expressing IgK, IgL, or translocated IgL, the authors found that the IgL locus contains multiple strong enhancer elements that are bound by the Ikaros transcription factor-coding gene (IKZF1). Even so, available patient data indicated that the multiple myeloma cases marked by IgL translocations did not seem to respond to so-called immunomodulatory imide (IMiD) drugs that target IKZF1.

From these and other data, the authors concluded that IgL-MYC translocations as a marker of poor prognosis, independent of other genetic abnormalities, with implications for diagnosis and treatment. The study was published on April 23, 2019, in the journal Nature Communications.

Related Links:
Emory University School of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.